CSL Ltd (CMXHF)
173.50
-6.50
(-3.61%)
USD |
OTCM |
Dec 16, 11:02
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 84.01B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 1.40% |
| Valuation | |
| PE Ratio | 31.83 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 5.726 |
| Price to Book Value | 4.838 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 1.450 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.6058 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 37.47% |
Profile
| CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world’s second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe. |
| URL | https://www.csl.com |
| Investor Relations URL | https://investors.csl.com/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | Feb. 13, 2025 (est.) |
| Last Earnings Release | Aug. 13, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 09, 2024 |
Ratings
Profile
| CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world’s second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe. |
| URL | https://www.csl.com |
| Investor Relations URL | https://investors.csl.com/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | Feb. 13, 2025 (est.) |
| Last Earnings Release | Aug. 13, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 09, 2024 |